HudsonAlpha Institute adopts Nucleofector Technology in pursuit of its Research Goals

The HudsonAlpha Institute for Biotechnology recognizes the Nucleofector Technology as an ideal tool for developing reproducible, non-viral based, optimized transfection protocols for the cell lines included in the National Cancer Institute's drug discovery panel.

Download the press release

Back to: Public Relations